SlideShare a Scribd company logo
Multi Drug Resistance Assay:
A New Dimension for Host
Directed Therapy
PRESENTED BY:
CYRIL JOSE
KESRIN AMRA
OP 1
Introduction
 Availabilility of many anti-TB drugs to treat
people with tuberculosis (TB), but
resistance to these drugs is a growing
problem.
 People with drug-resistant TB require
“second-line” TB drugs that, compared
with “first-line” TB drugs used to treat
drug-susceptible TB, cause more side
effects and must be taken for longer.
 A rapid and accurate test could identify
people with drug-resistant TB, likely
improve patient care, and reduce the
spread of drug-resistant TB.
Types of resistance
Rifampicin
resistance
• TB bacteria do
not respond to
rifampicin
therapy
• Require second
line treatment
Multi drug
resistance
• Resistant to
atleast
rifampicin and
isoniazid
• Need second
line of treatment
Extensively drug
resistant
• Resistant to first
and second line
drugs
• Resistant to
fluoroquinolones
Conventional therapy
1st line
Isoniazid
Rifampicin
Pyrazinamide
Ethambutol
2 nd line
Para amino
salicylic acid
Streptomycin
Ethionamide
Cycloserine
Selection of individualized MDR-TB
regimens
 Based on the patient's history of past drug use
and on DST of isoniazid, rifampicin, the second-line
injectable agents and a fluoroquinolone. Although
resistance can develop in less than 1 month, if a
patient has used a drug for more than 1 month with
persistently positive smears or cultures, the strain
should – as a general rule – be considered as
“probably resistant” to that drug, even if DST results
indicate that it is susceptible.
 Another important limitation is the turnaround time
for DST results…so the WHO recommends much
rapid and simpler Genotypic MDR assays.
Different levels of MDR observed are
 Cross resistance
 Different minimum inhibitory
concentration
 Resistance to one or more drug of a
particular group
MDR assays are conducted on
Sputum specimen
Culture isolates
Assay Methods
• Line Probe assay
• Loop mediated isothermal
amplification
• Oligonucleotide microarray
• Xpert MTB/RIF
Molecular methods
• Fluorescent light emitting diode
• Colorimetric assay
• MDR XDR Color testNon molecular
methods
WHO recommended MDR assays
Conventional phenotypic DST
 to evaluate emergence of additonal drug resistance.
 to confirm resistance to other drugs.
Genotype MTBDR assay
WHO recommends SL-LPA for patients with confirmed RR-TB or MDR TB as the
initial test to detect resistance to FQs & 2nd line injectable drugs.
Among patients prescribed conventional MDR-TB, MDR assays can help to decide
who would benefit from new medicines to strengthen the regimen
WHO recommended MDR-TB regimen
Treated with different combination of 2nd line drugs.
Short term MDR-TB regimen.
In patients with rifampicin-resistant or multidrug-resistant TB who have not been
previously treated with second-line drugs and in whom resistance to
fluoroquinolones and second-line injectable agents has been excluded or is
considered highly unlikely, a shorter MDR-TB regimen of 9-12 months may be used
instead of a conventional regimen (conditional recommendation, very low certainty
in the evidence)
Good quality
drugs
Political and
administrative
commitment
Good quality
diagnosis
Directly
observed
treatment
Systemic
monitoring
and
accountability
Elements
of DOTS
Problems associated with the DOTS strategy (observed in India)
Resistance to DOTS therapy reported
DOTS plus strategy yet to be launched to tackle the MDR-TB issue which
comprises of 2nd line drug.
DOTS strategy in India
Personalisation of medicines
Why do we generalise TB like most other diseases...???
Especially since MDR cases are advancing in current scenario...why do we
still follow the same treatment regimen in almost the entire population..???
Don’t you feel there is a need for MDR assays before prescribing an anti-
TB drugs..???
Why do we have to wait to ascertain the ineffectiveness of the regimen till
the patient is not responding to the treatment pattern...??
As a budding pharmacist...many of you all like me would be concerned to
protect the molecular integrity of the newly launched anti-TB drugs..!!!Due
to their haphzard prescription...!!!......Aren’t we...???
Challenges
Ahead...!!!!
India has 121 labs
performing XPERT
MTB/RIF.
Only 0.2% TB cases
reportedly undergoes DST
testing in these labs...!!!!
Will the newly launched
molecules bedaquilline and
Delamanid face the same
fate as streptomycin..????
Risks Strategy
prior treatment for tuberculosis as a risk
factor for drug resistant tuberculosis
Simultaneous MDR Genotypic assays
alongwith TB diagnosis for detecting
presence of any resistance to first line
drugs.
inadequate treatment in both the public
health system and the hospital system
because they have disease that is
resistant to isoniazid or rifampin (or
both) but are still given these first line
TB drugs as part of standard treatment)
• selection of treatment regimens on
the basis of testing for initial drug
resistance
• enhance the continuity of treatment
after patients leave the hospitals
Emergence of drug resistance by strains
due to genetic mutations allow them to
survive even in the presence of these
agents.
using several anti-TB agents
concurrently
Use of a shorter MDR-TB treatment
regimen
Multi Drug Resistance Assay: A new Dimension for Host Directed therapy

More Related Content

What's hot

Mdr tb
Mdr tbMdr tb
Treatment of Multidrug-resistant and Extensively Drug-Resistant Tuberculosis ...
Treatment of Multidrug-resistant and Extensively Drug-Resistant Tuberculosis ...Treatment of Multidrug-resistant and Extensively Drug-Resistant Tuberculosis ...
Treatment of Multidrug-resistant and Extensively Drug-Resistant Tuberculosis ...
WAidid
 
Mdr xdr TB
Mdr xdr TBMdr xdr TB
Mdr tb khaled latest
Mdr tb khaled latestMdr tb khaled latest
Mdr tb khaled latest
Khaled Hassan
 
General principles of antimicrobial therapy
General principles of antimicrobial therapyGeneral principles of antimicrobial therapy
General principles of antimicrobial therapy
Jitendra Chaturvedi
 
Optimal Antibiotic Strategies in ICU
Optimal Antibiotic Strategies in ICUOptimal Antibiotic Strategies in ICU
Optimal Antibiotic Strategies in ICU
Yazan Kherallah
 
Mdr tuberculosis
Mdr tuberculosisMdr tuberculosis
Mdr tuberculosis
Gyanshankar Mishra
 
Recent Advances in Multidrug-Resistant TB of HIV/TB coinfection.2013
Recent Advances in Multidrug-Resistant TB of HIV/TB coinfection.2013Recent Advances in Multidrug-Resistant TB of HIV/TB coinfection.2013
Recent Advances in Multidrug-Resistant TB of HIV/TB coinfection.2013
Hivlife Info
 
MDR/XDR by Dr Tasleem Arif
MDR/XDR by Dr Tasleem ArifMDR/XDR by Dr Tasleem Arif
MDR/XDR by Dr Tasleem Arif
TASLEEM ARIF
 
Mdr tuberculosis updates
Mdr tuberculosis updatesMdr tuberculosis updates
Mdr tuberculosis updates
Gyanshankar Mishra
 
Combination antibiotic therapy bacteremic pneumococcal pneumonia: PRO
Combination antibiotic therapy bacteremic pneumococcal pneumonia: PROCombination antibiotic therapy bacteremic pneumococcal pneumonia: PRO
Combination antibiotic therapy bacteremic pneumococcal pneumonia: PROIdibaps Respiratory Research Group
 
Treatment of tb with sirturo
Treatment of tb with sirturoTreatment of tb with sirturo
Treatment of tb with sirturoKishore Chinna
 
DRUG RESISTANT TUBERCULOSIS,DIAGNOSIS AND TREATMENT
DRUG RESISTANT TUBERCULOSIS,DIAGNOSIS AND TREATMENTDRUG RESISTANT TUBERCULOSIS,DIAGNOSIS AND TREATMENT
DRUG RESISTANT TUBERCULOSIS,DIAGNOSIS AND TREATMENT
Dr.Lalit Kumar
 
Combating drug resistance
Combating drug resistanceCombating drug resistance
Combating drug resistance
Ashok Jangra
 
Are you allergic to any medication?
Are you allergic to any medication?Are you allergic to any medication?
Are you allergic to any medication?
Mazdak Zamani
 

What's hot (17)

MDR TB
MDR TB MDR TB
MDR TB
 
Mdr tb
Mdr tbMdr tb
Mdr tb
 
Treatment of Multidrug-resistant and Extensively Drug-Resistant Tuberculosis ...
Treatment of Multidrug-resistant and Extensively Drug-Resistant Tuberculosis ...Treatment of Multidrug-resistant and Extensively Drug-Resistant Tuberculosis ...
Treatment of Multidrug-resistant and Extensively Drug-Resistant Tuberculosis ...
 
Mdr xdr TB
Mdr xdr TBMdr xdr TB
Mdr xdr TB
 
Avendano
AvendanoAvendano
Avendano
 
Mdr tb khaled latest
Mdr tb khaled latestMdr tb khaled latest
Mdr tb khaled latest
 
General principles of antimicrobial therapy
General principles of antimicrobial therapyGeneral principles of antimicrobial therapy
General principles of antimicrobial therapy
 
Optimal Antibiotic Strategies in ICU
Optimal Antibiotic Strategies in ICUOptimal Antibiotic Strategies in ICU
Optimal Antibiotic Strategies in ICU
 
Mdr tuberculosis
Mdr tuberculosisMdr tuberculosis
Mdr tuberculosis
 
Recent Advances in Multidrug-Resistant TB of HIV/TB coinfection.2013
Recent Advances in Multidrug-Resistant TB of HIV/TB coinfection.2013Recent Advances in Multidrug-Resistant TB of HIV/TB coinfection.2013
Recent Advances in Multidrug-Resistant TB of HIV/TB coinfection.2013
 
MDR/XDR by Dr Tasleem Arif
MDR/XDR by Dr Tasleem ArifMDR/XDR by Dr Tasleem Arif
MDR/XDR by Dr Tasleem Arif
 
Mdr tuberculosis updates
Mdr tuberculosis updatesMdr tuberculosis updates
Mdr tuberculosis updates
 
Combination antibiotic therapy bacteremic pneumococcal pneumonia: PRO
Combination antibiotic therapy bacteremic pneumococcal pneumonia: PROCombination antibiotic therapy bacteremic pneumococcal pneumonia: PRO
Combination antibiotic therapy bacteremic pneumococcal pneumonia: PRO
 
Treatment of tb with sirturo
Treatment of tb with sirturoTreatment of tb with sirturo
Treatment of tb with sirturo
 
DRUG RESISTANT TUBERCULOSIS,DIAGNOSIS AND TREATMENT
DRUG RESISTANT TUBERCULOSIS,DIAGNOSIS AND TREATMENTDRUG RESISTANT TUBERCULOSIS,DIAGNOSIS AND TREATMENT
DRUG RESISTANT TUBERCULOSIS,DIAGNOSIS AND TREATMENT
 
Combating drug resistance
Combating drug resistanceCombating drug resistance
Combating drug resistance
 
Are you allergic to any medication?
Are you allergic to any medication?Are you allergic to any medication?
Are you allergic to any medication?
 

Viewers also liked

Multidrug Resistant Malaria- Vani Vannappagari MBBS PhD
Multidrug Resistant Malaria- Vani Vannappagari MBBS PhDMultidrug Resistant Malaria- Vani Vannappagari MBBS PhD
Multidrug Resistant Malaria- Vani Vannappagari MBBS PhD
Eastern Pennsylvania Branch ASM
 
Gene delivery System
Gene delivery SystemGene delivery System
Gene delivery System
Nupur Gupta
 
ATYPICAL MYCOBACTERIA
ATYPICAL MYCOBACTERIAATYPICAL MYCOBACTERIA
ATYPICAL MYCOBACTERIA
Abhinav Srivastava
 
Plasmodium falciparum
Plasmodium falciparumPlasmodium falciparum
Plasmodium falciparum
Vita Amanah
 
Plasmodium falciparum
Plasmodium falciparumPlasmodium falciparum
Plasmodium falciparum
ayooy1992
 
Rntcp current guidelines
Rntcp current guidelinesRntcp current guidelines
Rntcp current guidelines
Daniel Augustine
 
Gene delivery system
Gene delivery systemGene delivery system
Gene delivery system
Anne Aparajitha
 
Tb management 2016
Tb management 2016Tb management 2016
Tb management 2016
Haripriya Uppala
 
Therapeutic drug monitoring
Therapeutic drug monitoringTherapeutic drug monitoring
Therapeutic drug monitoring
Urmila Aswar
 
Targeted drug delivery systems By Vishnu Datta M
Targeted drug delivery systems By Vishnu Datta MTargeted drug delivery systems By Vishnu Datta M
Targeted drug delivery systems By Vishnu Datta M
Vishnu Datta Maremanda
 
WHO and RNTCP guidelines - Tuberculosis management
WHO and RNTCP guidelines - Tuberculosis managementWHO and RNTCP guidelines - Tuberculosis management
WHO and RNTCP guidelines - Tuberculosis management
Dr. Pratyush Kumar
 
Targeted drug delivery system
Targeted drug delivery systemTargeted drug delivery system
Targeted drug delivery system
Strides Shasun pharmaceutical ltd
 
Malaria powerpoint
Malaria powerpointMalaria powerpoint
Malaria powerpoint
Hawkesdale P12 College
 
PLASMODIUM ( P. falciparum, P. malariae, P. ovale y P. vivax)
PLASMODIUM ( P. falciparum, P. malariae, P. ovale y P. vivax)PLASMODIUM ( P. falciparum, P. malariae, P. ovale y P. vivax)
PLASMODIUM ( P. falciparum, P. malariae, P. ovale y P. vivax)
Adriana Olivhdz
 
Therapeutic Drug Monitoring
Therapeutic Drug MonitoringTherapeutic Drug Monitoring
Therapeutic Drug MonitoringTulasi Raman
 
Nanotechnology ppt
Nanotechnology pptNanotechnology ppt
Nanotechnology ppt
kirtisingh2011
 

Viewers also liked (19)

Multidrug Resistant Malaria- Vani Vannappagari MBBS PhD
Multidrug Resistant Malaria- Vani Vannappagari MBBS PhDMultidrug Resistant Malaria- Vani Vannappagari MBBS PhD
Multidrug Resistant Malaria- Vani Vannappagari MBBS PhD
 
Gene delivery System
Gene delivery SystemGene delivery System
Gene delivery System
 
ATYPICAL MYCOBACTERIA
ATYPICAL MYCOBACTERIAATYPICAL MYCOBACTERIA
ATYPICAL MYCOBACTERIA
 
Plasmodium falciparum
Plasmodium falciparumPlasmodium falciparum
Plasmodium falciparum
 
Plasmodium falciparum
Plasmodium falciparumPlasmodium falciparum
Plasmodium falciparum
 
Rntcp current guidelines
Rntcp current guidelinesRntcp current guidelines
Rntcp current guidelines
 
Gene delivery system
Gene delivery systemGene delivery system
Gene delivery system
 
4.Dots
4.Dots4.Dots
4.Dots
 
Tb management 2016
Tb management 2016Tb management 2016
Tb management 2016
 
Therapeutic drug monitoring
Therapeutic drug monitoringTherapeutic drug monitoring
Therapeutic drug monitoring
 
Targeted drug delivery systems By Vishnu Datta M
Targeted drug delivery systems By Vishnu Datta MTargeted drug delivery systems By Vishnu Datta M
Targeted drug delivery systems By Vishnu Datta M
 
Plasmodium
PlasmodiumPlasmodium
Plasmodium
 
WHO and RNTCP guidelines - Tuberculosis management
WHO and RNTCP guidelines - Tuberculosis managementWHO and RNTCP guidelines - Tuberculosis management
WHO and RNTCP guidelines - Tuberculosis management
 
Targeted drug delivery system
Targeted drug delivery systemTargeted drug delivery system
Targeted drug delivery system
 
Malaria powerpoint
Malaria powerpointMalaria powerpoint
Malaria powerpoint
 
PLASMODIUM ( P. falciparum, P. malariae, P. ovale y P. vivax)
PLASMODIUM ( P. falciparum, P. malariae, P. ovale y P. vivax)PLASMODIUM ( P. falciparum, P. malariae, P. ovale y P. vivax)
PLASMODIUM ( P. falciparum, P. malariae, P. ovale y P. vivax)
 
Therapeutic Drug Monitoring
Therapeutic Drug MonitoringTherapeutic Drug Monitoring
Therapeutic Drug Monitoring
 
Nanotechnology ppt
Nanotechnology pptNanotechnology ppt
Nanotechnology ppt
 
Nanotechnology Based Drug Delivery
Nanotechnology Based Drug DeliveryNanotechnology Based Drug Delivery
Nanotechnology Based Drug Delivery
 

Similar to Multi Drug Resistance Assay: A new Dimension for Host Directed therapy

MDR-TB
MDR-TBMDR-TB
MDR-TB
9925752690
 
Treatment of Tuberculosis
Treatment of TuberculosisTreatment of Tuberculosis
Treatment of Tuberculosis
Gyanshankar Mishra
 
Drugresistanttuberculosis 100227020029 Phpapp01
Drugresistanttuberculosis 100227020029 Phpapp01Drugresistanttuberculosis 100227020029 Phpapp01
Drugresistanttuberculosis 100227020029 Phpapp01
TBandU (Tuberculosis and You)
 
WHO GUIDE LINE ON MDR.pptx
WHO GUIDE LINE ON MDR.pptxWHO GUIDE LINE ON MDR.pptx
WHO GUIDE LINE ON MDR.pptx
Dr Imran Shaikh
 
Management of DR-TB
Management of DR-TBManagement of DR-TB
Management of DR-TB
Bronson Munsaka
 
Mdr, xdr by dr tasleem arif
Mdr, xdr by dr tasleem arifMdr, xdr by dr tasleem arif
Mdr, xdr by dr tasleem arif
TASLEEM ARIF
 
1INTRO~1.PPT
1INTRO~1.PPT1INTRO~1.PPT
1INTRO~1.PPT
sebsibneway1
 
Multi Drug Resistant - Tuberculosis
Multi Drug Resistant - TuberculosisMulti Drug Resistant - Tuberculosis
Multi Drug Resistant - Tuberculosis
SouravSingh883127
 
Pmdt guidelines
Pmdt guidelinesPmdt guidelines
Pmdt guidelines
rohit mahavarkar
 
Recent Advances in Multidrug-Resistant TB of HIV/TB coinfection.2013
Recent Advances in Multidrug-Resistant TB of HIV/TB coinfection.2013Recent Advances in Multidrug-Resistant TB of HIV/TB coinfection.2013
Recent Advances in Multidrug-Resistant TB of HIV/TB coinfection.2013
hivlifeinfo
 
DSTslides_updated_FINAL.pdf
DSTslides_updated_FINAL.pdfDSTslides_updated_FINAL.pdf
DSTslides_updated_FINAL.pdf
AliNadeem41
 
MDR Tuberculosis Case Presentation & Some facts About MDR/XDR TB
MDR Tuberculosis Case Presentation & Some facts About MDR/XDR TBMDR Tuberculosis Case Presentation & Some facts About MDR/XDR TB
MDR Tuberculosis Case Presentation & Some facts About MDR/XDR TB
SMS Medical College, Jaipur
 
Updated Part -3 Management of TB.. DR. Kiran G. Piparva 2020 [Autosaved].pptx
Updated Part -3 Management of TB.. DR. Kiran G. Piparva 2020 [Autosaved].pptxUpdated Part -3 Management of TB.. DR. Kiran G. Piparva 2020 [Autosaved].pptx
Updated Part -3 Management of TB.. DR. Kiran G. Piparva 2020 [Autosaved].pptx
DrKGPiparvaPharmalec
 
Rntcp update
Rntcp update Rntcp update
Rntcp update
Gyanshankar Mishra
 
Multi Drug Resistant Tuberculosis
Multi Drug Resistant Tuberculosis Multi Drug Resistant Tuberculosis
Multi Drug Resistant Tuberculosis
Amer Alboush
 
TREATMENT of tb.pptx
TREATMENT of tb.pptxTREATMENT of tb.pptx
TREATMENT of tb.pptx
SahilVerma19852
 
MOLECULAR BASIS & MECHANISMS OF DRUG RESISTANCE IN MYCOBACTERIUM TUBERCULOSIS
MOLECULAR BASIS & MECHANISMS OF DRUG RESISTANCE IN MYCOBACTERIUM TUBERCULOSISMOLECULAR BASIS & MECHANISMS OF DRUG RESISTANCE IN MYCOBACTERIUM TUBERCULOSIS
MOLECULAR BASIS & MECHANISMS OF DRUG RESISTANCE IN MYCOBACTERIUM TUBERCULOSIS
Kalai Arasan
 
Tuberculosis treatment
Tuberculosis treatmentTuberculosis treatment
Tuberculosis treatment
Daniel David
 
tuberculosis management
tuberculosis managementtuberculosis management
tuberculosis management
alkabansal04
 

Similar to Multi Drug Resistance Assay: A new Dimension for Host Directed therapy (20)

MDR-TB
MDR-TBMDR-TB
MDR-TB
 
Treatment of Tuberculosis
Treatment of TuberculosisTreatment of Tuberculosis
Treatment of Tuberculosis
 
Drugresistanttuberculosis 100227020029 Phpapp01
Drugresistanttuberculosis 100227020029 Phpapp01Drugresistanttuberculosis 100227020029 Phpapp01
Drugresistanttuberculosis 100227020029 Phpapp01
 
XDR TB
XDR TBXDR TB
XDR TB
 
WHO GUIDE LINE ON MDR.pptx
WHO GUIDE LINE ON MDR.pptxWHO GUIDE LINE ON MDR.pptx
WHO GUIDE LINE ON MDR.pptx
 
Management of DR-TB
Management of DR-TBManagement of DR-TB
Management of DR-TB
 
Mdr, xdr by dr tasleem arif
Mdr, xdr by dr tasleem arifMdr, xdr by dr tasleem arif
Mdr, xdr by dr tasleem arif
 
1INTRO~1.PPT
1INTRO~1.PPT1INTRO~1.PPT
1INTRO~1.PPT
 
Multi Drug Resistant - Tuberculosis
Multi Drug Resistant - TuberculosisMulti Drug Resistant - Tuberculosis
Multi Drug Resistant - Tuberculosis
 
Pmdt guidelines
Pmdt guidelinesPmdt guidelines
Pmdt guidelines
 
Recent Advances in Multidrug-Resistant TB of HIV/TB coinfection.2013
Recent Advances in Multidrug-Resistant TB of HIV/TB coinfection.2013Recent Advances in Multidrug-Resistant TB of HIV/TB coinfection.2013
Recent Advances in Multidrug-Resistant TB of HIV/TB coinfection.2013
 
DSTslides_updated_FINAL.pdf
DSTslides_updated_FINAL.pdfDSTslides_updated_FINAL.pdf
DSTslides_updated_FINAL.pdf
 
MDR Tuberculosis Case Presentation & Some facts About MDR/XDR TB
MDR Tuberculosis Case Presentation & Some facts About MDR/XDR TBMDR Tuberculosis Case Presentation & Some facts About MDR/XDR TB
MDR Tuberculosis Case Presentation & Some facts About MDR/XDR TB
 
Updated Part -3 Management of TB.. DR. Kiran G. Piparva 2020 [Autosaved].pptx
Updated Part -3 Management of TB.. DR. Kiran G. Piparva 2020 [Autosaved].pptxUpdated Part -3 Management of TB.. DR. Kiran G. Piparva 2020 [Autosaved].pptx
Updated Part -3 Management of TB.. DR. Kiran G. Piparva 2020 [Autosaved].pptx
 
Rntcp update
Rntcp update Rntcp update
Rntcp update
 
Multi Drug Resistant Tuberculosis
Multi Drug Resistant Tuberculosis Multi Drug Resistant Tuberculosis
Multi Drug Resistant Tuberculosis
 
TREATMENT of tb.pptx
TREATMENT of tb.pptxTREATMENT of tb.pptx
TREATMENT of tb.pptx
 
MOLECULAR BASIS & MECHANISMS OF DRUG RESISTANCE IN MYCOBACTERIUM TUBERCULOSIS
MOLECULAR BASIS & MECHANISMS OF DRUG RESISTANCE IN MYCOBACTERIUM TUBERCULOSISMOLECULAR BASIS & MECHANISMS OF DRUG RESISTANCE IN MYCOBACTERIUM TUBERCULOSIS
MOLECULAR BASIS & MECHANISMS OF DRUG RESISTANCE IN MYCOBACTERIUM TUBERCULOSIS
 
Tuberculosis treatment
Tuberculosis treatmentTuberculosis treatment
Tuberculosis treatment
 
tuberculosis management
tuberculosis managementtuberculosis management
tuberculosis management
 

Recently uploaded

💘Ludhiana ℂall Girls 📞]][89011★83002][[ 📱 ❤ESCORTS service in Ludhiana💃💦Ludhi...
💘Ludhiana ℂall Girls 📞]][89011★83002][[ 📱 ❤ESCORTS service in Ludhiana💃💦Ludhi...💘Ludhiana ℂall Girls 📞]][89011★83002][[ 📱 ❤ESCORTS service in Ludhiana💃💦Ludhi...
💘Ludhiana ℂall Girls 📞]][89011★83002][[ 📱 ❤ESCORTS service in Ludhiana💃💦Ludhi...
ranishasharma67
 
Anatomy and Physiology Chapter-16_Digestive-System.pptx
Anatomy and Physiology Chapter-16_Digestive-System.pptxAnatomy and Physiology Chapter-16_Digestive-System.pptx
Anatomy and Physiology Chapter-16_Digestive-System.pptx
shanicedivinagracia2
 
ABDOMINAL COMPARTMENT SYSNDROME
ABDOMINAL COMPARTMENT SYSNDROMEABDOMINAL COMPARTMENT SYSNDROME
ABDOMINAL COMPARTMENT SYSNDROME
Rommel Luis III Israel
 
POLYCYSTIC OVARIAN SYNDROME (PCOS)......
POLYCYSTIC OVARIAN SYNDROME (PCOS)......POLYCYSTIC OVARIAN SYNDROME (PCOS)......
POLYCYSTIC OVARIAN SYNDROME (PCOS)......
Ameena Kadar
 
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Navigating Challenges: Mental Health, Legislation, and the Prison System in B...
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...
Guillermo Rivera
 
The Docs PPG - 30.05.2024.pptx..........
The Docs PPG - 30.05.2024.pptx..........The Docs PPG - 30.05.2024.pptx..........
The Docs PPG - 30.05.2024.pptx..........
TheDocs
 
Medical Technology Tackles New Health Care Demand - Research Report - March 2...
Medical Technology Tackles New Health Care Demand - Research Report - March 2...Medical Technology Tackles New Health Care Demand - Research Report - March 2...
Medical Technology Tackles New Health Care Demand - Research Report - March 2...
pchutichetpong
 
the IUA Administrative Board and General Assembly meeting
the IUA Administrative Board and General Assembly meetingthe IUA Administrative Board and General Assembly meeting
the IUA Administrative Board and General Assembly meeting
ssuser787e5c1
 
CANCER CANCER CANCER CANCER CANCER CANCER
CANCER  CANCER  CANCER  CANCER  CANCER CANCERCANCER  CANCER  CANCER  CANCER  CANCER CANCER
CANCER CANCER CANCER CANCER CANCER CANCER
KRISTELLEGAMBOA2
 
GLOBAL WARMING BY PRIYA BHOJWANI @..pptx
GLOBAL WARMING BY PRIYA BHOJWANI @..pptxGLOBAL WARMING BY PRIYA BHOJWANI @..pptx
GLOBAL WARMING BY PRIYA BHOJWANI @..pptx
priyabhojwani1200
 
Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤
Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤
Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤
ranishasharma67
 
Navigating the Health Insurance Market_ Understanding Trends and Options.pdf
Navigating the Health Insurance Market_ Understanding Trends and Options.pdfNavigating the Health Insurance Market_ Understanding Trends and Options.pdf
Navigating the Health Insurance Market_ Understanding Trends and Options.pdf
Enterprise Wired
 
Immunity to Veterinary parasitic infections power point presentation
Immunity to Veterinary parasitic infections power point presentationImmunity to Veterinary parasitic infections power point presentation
Immunity to Veterinary parasitic infections power point presentation
BeshedaWedajo
 
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdf
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfCHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdf
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdf
Sachin Sharma
 
Dimensions of Healthcare Quality
Dimensions of Healthcare QualityDimensions of Healthcare Quality
Dimensions of Healthcare Quality
Naeemshahzad51
 
Nursing Care of Client With Acute And Chronic Renal Failure.ppt
Nursing Care of Client With Acute And Chronic Renal Failure.pptNursing Care of Client With Acute And Chronic Renal Failure.ppt
Nursing Care of Client With Acute And Chronic Renal Failure.ppt
Rommel Luis III Israel
 
Telehealth Psychology Building Trust with Clients.pptx
Telehealth Psychology Building Trust with Clients.pptxTelehealth Psychology Building Trust with Clients.pptx
Telehealth Psychology Building Trust with Clients.pptx
The Harvest Clinic
 
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...
Kumar Satyam
 
Artificial Intelligence to Optimize Cardiovascular Therapy
Artificial Intelligence to Optimize Cardiovascular TherapyArtificial Intelligence to Optimize Cardiovascular Therapy
Artificial Intelligence to Optimize Cardiovascular Therapy
Iris Thiele Isip-Tan
 
Navigating Healthcare with Telemedicine
Navigating Healthcare with  TelemedicineNavigating Healthcare with  Telemedicine
Navigating Healthcare with Telemedicine
Iris Thiele Isip-Tan
 

Recently uploaded (20)

💘Ludhiana ℂall Girls 📞]][89011★83002][[ 📱 ❤ESCORTS service in Ludhiana💃💦Ludhi...
💘Ludhiana ℂall Girls 📞]][89011★83002][[ 📱 ❤ESCORTS service in Ludhiana💃💦Ludhi...💘Ludhiana ℂall Girls 📞]][89011★83002][[ 📱 ❤ESCORTS service in Ludhiana💃💦Ludhi...
💘Ludhiana ℂall Girls 📞]][89011★83002][[ 📱 ❤ESCORTS service in Ludhiana💃💦Ludhi...
 
Anatomy and Physiology Chapter-16_Digestive-System.pptx
Anatomy and Physiology Chapter-16_Digestive-System.pptxAnatomy and Physiology Chapter-16_Digestive-System.pptx
Anatomy and Physiology Chapter-16_Digestive-System.pptx
 
ABDOMINAL COMPARTMENT SYSNDROME
ABDOMINAL COMPARTMENT SYSNDROMEABDOMINAL COMPARTMENT SYSNDROME
ABDOMINAL COMPARTMENT SYSNDROME
 
POLYCYSTIC OVARIAN SYNDROME (PCOS)......
POLYCYSTIC OVARIAN SYNDROME (PCOS)......POLYCYSTIC OVARIAN SYNDROME (PCOS)......
POLYCYSTIC OVARIAN SYNDROME (PCOS)......
 
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Navigating Challenges: Mental Health, Legislation, and the Prison System in B...
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...
 
The Docs PPG - 30.05.2024.pptx..........
The Docs PPG - 30.05.2024.pptx..........The Docs PPG - 30.05.2024.pptx..........
The Docs PPG - 30.05.2024.pptx..........
 
Medical Technology Tackles New Health Care Demand - Research Report - March 2...
Medical Technology Tackles New Health Care Demand - Research Report - March 2...Medical Technology Tackles New Health Care Demand - Research Report - March 2...
Medical Technology Tackles New Health Care Demand - Research Report - March 2...
 
the IUA Administrative Board and General Assembly meeting
the IUA Administrative Board and General Assembly meetingthe IUA Administrative Board and General Assembly meeting
the IUA Administrative Board and General Assembly meeting
 
CANCER CANCER CANCER CANCER CANCER CANCER
CANCER  CANCER  CANCER  CANCER  CANCER CANCERCANCER  CANCER  CANCER  CANCER  CANCER CANCER
CANCER CANCER CANCER CANCER CANCER CANCER
 
GLOBAL WARMING BY PRIYA BHOJWANI @..pptx
GLOBAL WARMING BY PRIYA BHOJWANI @..pptxGLOBAL WARMING BY PRIYA BHOJWANI @..pptx
GLOBAL WARMING BY PRIYA BHOJWANI @..pptx
 
Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤
Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤
Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤
 
Navigating the Health Insurance Market_ Understanding Trends and Options.pdf
Navigating the Health Insurance Market_ Understanding Trends and Options.pdfNavigating the Health Insurance Market_ Understanding Trends and Options.pdf
Navigating the Health Insurance Market_ Understanding Trends and Options.pdf
 
Immunity to Veterinary parasitic infections power point presentation
Immunity to Veterinary parasitic infections power point presentationImmunity to Veterinary parasitic infections power point presentation
Immunity to Veterinary parasitic infections power point presentation
 
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdf
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfCHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdf
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdf
 
Dimensions of Healthcare Quality
Dimensions of Healthcare QualityDimensions of Healthcare Quality
Dimensions of Healthcare Quality
 
Nursing Care of Client With Acute And Chronic Renal Failure.ppt
Nursing Care of Client With Acute And Chronic Renal Failure.pptNursing Care of Client With Acute And Chronic Renal Failure.ppt
Nursing Care of Client With Acute And Chronic Renal Failure.ppt
 
Telehealth Psychology Building Trust with Clients.pptx
Telehealth Psychology Building Trust with Clients.pptxTelehealth Psychology Building Trust with Clients.pptx
Telehealth Psychology Building Trust with Clients.pptx
 
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...
 
Artificial Intelligence to Optimize Cardiovascular Therapy
Artificial Intelligence to Optimize Cardiovascular TherapyArtificial Intelligence to Optimize Cardiovascular Therapy
Artificial Intelligence to Optimize Cardiovascular Therapy
 
Navigating Healthcare with Telemedicine
Navigating Healthcare with  TelemedicineNavigating Healthcare with  Telemedicine
Navigating Healthcare with Telemedicine
 

Multi Drug Resistance Assay: A new Dimension for Host Directed therapy

  • 1. Multi Drug Resistance Assay: A New Dimension for Host Directed Therapy PRESENTED BY: CYRIL JOSE KESRIN AMRA OP 1
  • 2. Introduction  Availabilility of many anti-TB drugs to treat people with tuberculosis (TB), but resistance to these drugs is a growing problem.  People with drug-resistant TB require “second-line” TB drugs that, compared with “first-line” TB drugs used to treat drug-susceptible TB, cause more side effects and must be taken for longer.  A rapid and accurate test could identify people with drug-resistant TB, likely improve patient care, and reduce the spread of drug-resistant TB.
  • 3. Types of resistance Rifampicin resistance • TB bacteria do not respond to rifampicin therapy • Require second line treatment Multi drug resistance • Resistant to atleast rifampicin and isoniazid • Need second line of treatment Extensively drug resistant • Resistant to first and second line drugs • Resistant to fluoroquinolones
  • 4. Conventional therapy 1st line Isoniazid Rifampicin Pyrazinamide Ethambutol 2 nd line Para amino salicylic acid Streptomycin Ethionamide Cycloserine
  • 5.
  • 6. Selection of individualized MDR-TB regimens  Based on the patient's history of past drug use and on DST of isoniazid, rifampicin, the second-line injectable agents and a fluoroquinolone. Although resistance can develop in less than 1 month, if a patient has used a drug for more than 1 month with persistently positive smears or cultures, the strain should – as a general rule – be considered as “probably resistant” to that drug, even if DST results indicate that it is susceptible.  Another important limitation is the turnaround time for DST results…so the WHO recommends much rapid and simpler Genotypic MDR assays.
  • 7. Different levels of MDR observed are  Cross resistance  Different minimum inhibitory concentration  Resistance to one or more drug of a particular group MDR assays are conducted on Sputum specimen Culture isolates
  • 8. Assay Methods • Line Probe assay • Loop mediated isothermal amplification • Oligonucleotide microarray • Xpert MTB/RIF Molecular methods • Fluorescent light emitting diode • Colorimetric assay • MDR XDR Color testNon molecular methods
  • 9. WHO recommended MDR assays Conventional phenotypic DST  to evaluate emergence of additonal drug resistance.  to confirm resistance to other drugs. Genotype MTBDR assay WHO recommends SL-LPA for patients with confirmed RR-TB or MDR TB as the initial test to detect resistance to FQs & 2nd line injectable drugs. Among patients prescribed conventional MDR-TB, MDR assays can help to decide who would benefit from new medicines to strengthen the regimen WHO recommended MDR-TB regimen Treated with different combination of 2nd line drugs. Short term MDR-TB regimen. In patients with rifampicin-resistant or multidrug-resistant TB who have not been previously treated with second-line drugs and in whom resistance to fluoroquinolones and second-line injectable agents has been excluded or is considered highly unlikely, a shorter MDR-TB regimen of 9-12 months may be used instead of a conventional regimen (conditional recommendation, very low certainty in the evidence)
  • 10. Good quality drugs Political and administrative commitment Good quality diagnosis Directly observed treatment Systemic monitoring and accountability Elements of DOTS
  • 11. Problems associated with the DOTS strategy (observed in India) Resistance to DOTS therapy reported DOTS plus strategy yet to be launched to tackle the MDR-TB issue which comprises of 2nd line drug. DOTS strategy in India
  • 12. Personalisation of medicines Why do we generalise TB like most other diseases...??? Especially since MDR cases are advancing in current scenario...why do we still follow the same treatment regimen in almost the entire population..??? Don’t you feel there is a need for MDR assays before prescribing an anti- TB drugs..??? Why do we have to wait to ascertain the ineffectiveness of the regimen till the patient is not responding to the treatment pattern...?? As a budding pharmacist...many of you all like me would be concerned to protect the molecular integrity of the newly launched anti-TB drugs..!!!Due to their haphzard prescription...!!!......Aren’t we...???
  • 13. Challenges Ahead...!!!! India has 121 labs performing XPERT MTB/RIF. Only 0.2% TB cases reportedly undergoes DST testing in these labs...!!!! Will the newly launched molecules bedaquilline and Delamanid face the same fate as streptomycin..????
  • 14. Risks Strategy prior treatment for tuberculosis as a risk factor for drug resistant tuberculosis Simultaneous MDR Genotypic assays alongwith TB diagnosis for detecting presence of any resistance to first line drugs. inadequate treatment in both the public health system and the hospital system because they have disease that is resistant to isoniazid or rifampin (or both) but are still given these first line TB drugs as part of standard treatment) • selection of treatment regimens on the basis of testing for initial drug resistance • enhance the continuity of treatment after patients leave the hospitals Emergence of drug resistance by strains due to genetic mutations allow them to survive even in the presence of these agents. using several anti-TB agents concurrently Use of a shorter MDR-TB treatment regimen